{
    "clinical_study": {
        "@rank": "144782", 
        "arm_group": [
            {
                "arm_group_label": "Dydrogesterone", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients allocated to the dydrogesterone group will receive oral dydrogesterone 40mg stat, followed by 10mg orally three times a day, and placebo will be used in the control group accordingly. Patients will be followed up with weekly pelvic ultrasound till 12 completed weeks of gestation or 1 week after the bleeding stopped, whichever is longer."
            }, 
            {
                "arm_group_label": "Placebo pill", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Patients allocated to the dydrogesterone group will receive oral dydrogesterone 40mg stat, followed by 10mg orally three times a day, and placebo will be used in the control group accordingly. Patients will be followed up with weekly pelvic ultrasound till 12 completed weeks of gestation or 1 week after the bleeding stopped, whichever is longer."
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this study is to determine whether the dydrogesterone therapy is associated with\n      reduction in miscarriage in women with first trimester threatened miscarriage. The\n      hypothesis is that the dydrogesterone therapy will significantly reduce the risk of\n      miscarriage in women with threatened miscarriage."
        }, 
        "brief_title": "Randomized Double-blind Controlled Trial of Use of Dydrogesterone in Threatened Miscarriage", 
        "condition": [
            "First Trimester Threatened Miscarriage Treatment", 
            "Dydrogesterone Therapy"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Abortion, Spontaneous", 
                "Abortion, Threatened"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age of women from 18-40 years at the time of recruitment (not beyond 40th birthday)\n\n          -  Spontaneous conception\n\n          -  Absence of systemic illness or fever\n\n          -  No history of passage of conception material\n\n          -  Gestation less than 12 completed weeks\n\n          -  A singleton intrauterine fetus with fetal heart pulsation confirmed on pelvic\n             scanning\n\n        Exclusion Criteria:\n\n          -  Age of women >40 years at the time of recruitment\n\n          -  Assisted conception including intrauterine insemination and in vitro fertilization\n             treatment\n\n          -  History of recurrent miscarriage\n\n          -  History of chromosomal abnormalities\n\n          -  History of positive anti-phospholipid antibody\n\n          -  Presence of congenital uterine abnormality on pelvic scanning\n\n          -  Heavy vaginal bleeding requiring surgical intervention\n\n          -  Severe abdominal pain\n\n          -  Twin pregnancy on scanning\n\n          -  Absence of cardiac pulsation in a fetal pole on transvaginal scanning\n\n          -  Use of progesterone treatment for threatened miscarriage before recruitment"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "40 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "400", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 29, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02128685", 
            "org_study_id": "UW 13-292"
        }, 
        "intervention": [
            {
                "arm_group_label": "Dydrogesterone", 
                "intervention_name": "Dydrogesterone", 
                "intervention_type": "Drug", 
                "other_name": "Duphaston"
            }, 
            {
                "arm_group_label": "Placebo pill", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Dydrogesterone"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Threatened miscarriage", 
            "Dydrogesterone", 
            "Randomized controlled trial"
        ], 
        "lastchanged_date": "May 2, 2014", 
        "location": {
            "contact": {
                "email": "dcmanka@gmail.com", 
                "last_name": "Man Ka Diana Chan, MBBS(HK)", 
                "phone": "22554517"
            }, 
            "facility": {
                "address": {
                    "city": "Hong Kong", 
                    "country": "China"
                }, 
                "name": "Department of Obstetrics & Gynaecology, Queen Mary Hospital"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized Double-blind Controlled Trial of Use of Dydrogesterone in Women With Threatened Miscarriage in the First Trimester", 
        "overall_contact": {
            "email": "dcmanka@gmail.com", 
            "last_name": "Man Ka Diana Chan, MBBS(HK)", 
            "phone": "22554517"
        }, 
        "overall_official": {
            "affiliation": "Department of Obstetrics & Gynaecology, Queen Mary Hospital", 
            "last_name": "Man Ka Diana Chan, MBBS(HK)", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Hong Kong: Ethics Committee"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The chance of miscarriage before 20 weeks of gestation", 
            "safety_issue": "No", 
            "time_frame": "20 weeks of gestation"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02128685"
        }, 
        "responsible_party": {
            "investigator_affiliation": "The University of Hong Kong", 
            "investigator_full_name": "CHAN MAN KA DIANA", 
            "investigator_title": "Resident", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "The incidences of antepartum hemorrhage, placenta previa, pregnancy-induced hypertension, intrauterine death, congenital abnormality, preterm labour (28-36 weeks), low birth weight at term (<2500g) and full term delivery", 
            "safety_issue": "Yes", 
            "time_frame": "Antenatal till delivery"
        }, 
        "source": "The University of Hong Kong", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "The University of Hong Kong", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2015", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}